The Turkish Journal of Pediatrics 2011 , Vol 53 , Num 1
Secondary Childhood Acute Myeloid Leukemia With Complex Karyotypic Anomalies İncluding Monosomy 7, Monosomy 5 And Translocation (1;10) After ¹³¹I- Metaiodobenzylguanidine Therapy For Relapsed Neuroblastoma
1Department of Pediatric Oncology, Dr. Sami Ulus Children’s Hospital, and 2Department of Basic Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey İncesoy-Özdemir S, Bozkurt C, Yüksek N, Ören AC, Şahin G, Bozkurt S, Ertem U. Secondary childhood acute myeloid leukemia with complex karyotypic anomalies including monosomy 7, monosomy 5 and translocation (1;10) after ¹³¹I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. Turk J Pediatr 2011; 53: 83-86.

The prognosis for relapsing or refractory neuroblastoma (NB) remains dismal, with a five-year disease-free survival of <20%, and no effective salvage treatment has been identified so far. ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) has come to play an essential role in the imaging and therapy of NB over the past 30 years. The role of ¹³¹I-MIBG in the treatment of NB is continually expanding. ¹³¹I-MIBG treatment together with cumulative doses of other alkylating agents has potential serious late side effects such as myelodysplasia and leukemia, although rare. We describe a secondary acute myeloid leukemia case with complex karyotypic anomalies that included monosomy 5, monosomy 7 and translocation (1;10) in a child with relapsed NB who received therapeutic ¹³¹I-MIBG. Keywords : ¹³¹I-metaiodobenzylguanidine, monosomy 5 and 7, neuroblastoma, secondary myeloid leukemia, translocation (1;10).

Copyright © 2016